This filing provides an overview of analyst expectations and recent price target adjustments for Johnson & Johnson ahead of its Q3 earnings release. While most analysts maintain 'Buy' or 'Overweight' ratings and have increased price targets, the consensus EPS forecast is lower than the prior year, indicating potential headwinds.
This filing details analyst sentiment and financial forecasts for Johnson & Johnson (JNJ) leading up to its Q3 earnings report. Several 'most accurate' analysts have recently raised their price targets and maintained positive ratings, suggesting a generally optimistic outlook on the stock's future performance. However, the consensus EPS forecast for Q3 is lower year-over-year, which could temper investor enthusiasm despite the revenue growth projection. For traders, the short-term implication is increased volatility around the earnings release, as the market reacts to the actual results compared to these updated expectations. Long-term, the positive clinical trial findings for Tremfya and Carvykti could be a growth driver, but the immediate focus will be on the Q3 numbers and any forward guidance.